Fortrea Holdings Inc. (FTRE) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide.

Total Revenue Chart for Fortrea Holdings Inc.

Fortrea Holdings Inc. (FTRE) revenue for FY2025 was USD 2.7B, a 1.0% change from FY2024. Fortrea Holdings Inc.'s revenue grew from USD 2.6B in 2020 to USD 2.7B in 2025 (5.5% over 5 years). Revenue compound annual growth rate: 5-year CAGR of 1.1%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$2.25B
Implied Share Price
$23.63
Enterprise Value
$2.03B
Revenue (TTM)
$2.68B
EBITDA
$98.30M
Profit Margin
-3.18%
Trailing P/E
—
Forward P/E
6.12
Price/Book (MRQ)
1.48
Price/Sales (TTM)
0.84
EV/EBITDA
92.35
EV/Revenue
0.74
Dividend Yield
—
Book Value
$5.51
Free Cash Flow (FY2025)
$88.30M
Free Cash Flow Yield
3.93%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.